International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 10.01.2020
two researchers
covid screening dogs at the airport
Understanding Second and Third Waves of COVID-19 as We Head into Autumn
“We had all hoped COVID-19 would be behind us by now,” says IMF Chairman Dr. Brian G.M. Durie. But as cases rise in many parts of the U.S. and the world, we need to “stay vigilant.” Dr. Durie shares the latest pandemic news and six steps to strengthening your resilience.
Blog Button
“Everybody Loves Raymond” Cast Reunites for a Virtual Table Read
Join us on Friday, October 23, 2020, at 6 p.m. PT / 9 p.m. ET for an exclusive virtual table read reviving the classic sitcom “Everybody Loves Raymond.” Actor and comedian Ray Romano returns to host and will be joined by his former fellow cast members Patricia Heaton, Brad Garrett, Monica Horan, and show creator Phil Rosenthal. While the table read will be streamed free of charge, your donations will benefit the Peter Boyle Research Fund and the Black Swan Research Initiative®.
Register NOW for this FREE Patient & Family Webinar
The Patient & Family Webinar, Multiple Myeloma — New Treatments, Diversity, and Caregiver Support, will take place on Saturday, October 3, 2020, at 7 a.m. PT / 10 a.m. ET. This free two-hour webinar features a panel discussion led by IMF Chief Medical Officer Dr. Joseph Mikhael of Translational Genomics Research Institute (TGen). Panelists include Deepu Madduri, MD of Tisch Cancer Institute/Mount Sinai Hospital; Craig Emmitt Cole, MD of Michigan State University; and Beth Faiman PhD, MSN, APRN-BC, AOCN, FAAN of Cleveland Clinic Taussig Cancer Institute. IMF President, Founder, and CEO Susie Durie and IMF Vice President of Support Groups Robin Tuohy will lead a special segment dedicated to caregiver support.
patient and pharmacist discussion between counter
An Expanded Access Program in the US for Melflufen in Triple-Class Refractory Mulitple Myeloma Opens
Today, the open-label Expanded Access Program, sEAPort, for eligible U.S. patients, formally opens. "Melflufen (INN melphalan flufenamide), is currently being evaluated in several clinical studies as a treatment for patients with triple-class refractory multiple myeloma. The sEAPort program is available to adults, age 18 and older, who have received at least two prior lines of therapy and whose multiple myeloma is refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody, (i.e., triple-class refractory multiple myeloma patients)."
inside hawaiian house
And This Too Shall Pass….
Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself just minutes from the Hawaiian coastline. Note: Bookings will be in the future based on mutual availability with you and the property owner.
Should fish testing be done at relapse
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

Should FiSH testing be done at relapse?
Watch Now
Clinical Trials
OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Upcoming Events
Watch a Replay
IMF Patient & Family Webinar

Smile More Auction
Laughs 4 Life

Learn More
Legacy for Lily

Click here to see all events

We Thank Our Sponsors:

Amgen; Bristol-Myers Squibb; Genentech; GSK; Oncopeptides, Inc.; Sanofi-Genzyme; and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page